SRC and non-small cell lung carcinoma: Remarkably enough, also lapatinib-resistant breast cancer as well as erlotinib-resistant non-small cell lung cancer cells harbored increased integrin β1 expression and Src phosphorylation levels [68, 69] suggesting also a contribution to tyrosine kinase inhibitor resistance.